Claims for Patent: 8,491,895

Summary for Patent: 8,491,895

Title:	Methods of treating cancer with human monoclonal antibodies to CTLA-4
Abstract:	In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
Inventor(s):	Hanson; Douglas Charles (Niantic, CT), Neveu; Mark Joseph (Hartford, CT), Mueller; Eileen Elliott (Old Lyme, CT), Hanke; Jeffrey Herbert (Reading, MA), Gilman; Steven Christopher (Cambridge, MA), Davis; C. Geoffrey (Burlingame, CA), Corvalan; Jose Ramon (Foster City, CA)
Assignee:	Amgen Fremont Inc. (Thousand Oaks, CA) Pfizer Inc. (New York, NY)
Application Number:	13/399,448
Patent Claims:	1. A method for treating cancer in a subject, comprising the step of administering to the subject an antibody or an antigen-binding portion thereof that binds to CTLA-4, wherein said antibody comprises the heavy chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 70 and the light chain CDR1, CDR2, and CDR3 amino acid sequences in SEQ ID NO: 71. 2. The method according to claim 1, wherein said antibody comprises the heavy chain variable domain amino acid sequence in SEQ ID NO: 70 and the light chain variable domain amino acid sequence in SEQ ID NO: 71. 3. The method according to claim 1, wherein said antibody comprises the heavy chain amino acid sequence in SEQ ID NO: 70 and the light chain amino acid sequence in SEQ ID NO: 71. 4. A method for treating cancer in a subject, comprising the step of administering to the subject an antibody whose heavy chain comprises the amino acid sequence of SEQ ID NO: 70 and whose light chain comprises the amino acid sequence of SEQ ID NO: 71. 5. A method for treating cancer in a subject, comprising the step of administering to the subject an antibody or an antigen-binding portion thereof that binds to CTLA-4, wherein said antibody comprises the heavy chain variable domain amino acid sequence in SEQ ID NO: 80. 6. The method according to claim 5, wherein said antibody comprises the amino acid sequence of SEQ ID NO: 70. 7. A method for treating cancer in a subject, comprising the step of administering to the subject an antibody or an antigen-binding portion thereof that binds to CTLA-4, wherein said antibody comprises the light chain variable domain amino acid sequence in SEQ ID NO: 22. 8. The method according to claim 7, wherein said antibody comprises the amino acid sequence of SEQ ID NO: 71. 9. The method according to claim 1, wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody. 10. The method according to claim 4, wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody. 11. The method according to claim 5, wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody. 12. The method according to claim 7, wherein said antibody or antigen-binding portion is an Fab fragment, an F(ab').sub.2 fragment, an F.sub.v fragment, a single chain antibody, or a bispecific antibody. 13. The method according to claim 1, wherein said antibody is an immunoglobulin G (IgG) molecule. 14. The method according to claim 4, wherein said antibody is an immunoglobulin G (IgG) molecule. 15. The method according to claim 5, wherein said antibody is an immunoglobulin G (IgG) molecule. 16. The method according to claim 7, wherein said antibody is an immunoglobulin G (IgG) molecule. 17. The method according to claim 1, wherein said cancer comprises a tumor. 18. The method according to claim 4, wherein said cancer comprises a tumor. 19. The method according to claim 5, wherein said cancer comprises a tumor. 20. The method according to claim 7, wherein said cancer comprises a tumor.

Details for Patent 8,491,895

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Octapharma Pharmazeutika Produktionsges.m.b.h.	CUTAQUIG	immune globulin subcutaneous (human)-hipp	Solution	125668	December 12, 2018		2032-02-17